SCHEMBL12065280

SCHEMBL12065280

CCOc1ccc2[nH]c(C(OC)c3ccc(OC(F)(F)F)cc3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MLKL Q8NB16 4/20 0.46
▸ SCN10A Q9Y5Y9 3/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ PDE2A O00408 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CBFB Q13951 1/20 0.35
▸ HPGD P15428 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12066012 0.91 MEN1 (0.45) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL12065627 0.89 MEN1 (0.46) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL12065638 0.87 MEN1 (0.40) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL12066005 0.86 MEN1 (0.51) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL14762836 0.85 MLKL (0.48) MLKLSCN10APDE2AHPGDALDH1A1
SCHEMBL12066025 0.85 SCN10A (0.45) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL14763049 0.85 MEN1 (0.40) SCN10AMEN1HTTKMT2APDE2A
SCHEMBL14762773 0.85 SCN10A (0.43) MLKLSCN10AMEN1HTTKMT2A
SCHEMBL14762657 0.84 MLKL (0.47) MLKLSCN10APDE2AHPGDMAPT
SCHEMBL12065635 0.82 MLKL (0.68) MLKLSCN10ACBFBALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US claimed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US claimed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MLKL 2378/4885SCN10A 85/4885MEN1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback